Search results
Author(s):
James Gammie
Added:
2 years ago
In this short interview, Dr James Gammie (University of Maryland Medical Center, MD, US) discusses the findings from surgical trial assessing the benefit of concomitant tricuspid repair during mitral valve surgery. The trial, presented at AHA 2021, demonstrated that at 2 years, TA had no impact on MACCE, survival, or QOL.
Discussion Points
1. Reasoning for this Study
2. Study Design and…
View more
Author(s):
Jean-Bernard Masson
,
Jessica Forcillo
Added:
2 years ago
Mohammed Mohsin Uzzaman
Author
ESC 23: The SurHyb Trial
Author(s):
Alan Bulava
Added:
7 months ago
Video
A Pieter Kappetein
Job title: Consultant Cardiothoracic Surgeon, Professor and Chair of the residency program
Author
Author(s):
Shu-I Lin
,
Mizuki Miura
,
Francesco Maisano
,
et al
Added:
3 years ago
Moderate-to-severe tricuspid regurgitation (TR) is estimated to affect more than 1.6 million people in the US. However, fewer than 8,000 tricuspid valve operations are performed each year.1,2 There is clearly an unmet need for a tricuspid valve (TV) intervention. There has been rapid development in the field of transcatheter aortic and mitral valve interventions and percutaneous management of…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more
Author(s):
Astrid Apor
,
Andrea Nagy
,
Anikó Nagy
,
et al
Added:
3 years ago
Abstract
Mitral regurgitation (MR) is the most commonly found valvular lesion in echocardiography laboratories. Moderate and severe mitral regurgitation have proven to be associated with increased morbidity and mortality, and surgical reconstruction is recommended in severe cases whenever feasible. Three-dimensional echocardiography (3DE) is superior to conventional echocardiography in the…
View more
Joseph C Cleveland Jr
Research Area(s) / Expertise:
Author
Expertise
Author(s):
Michael F Morris
,
Philip A Araoz
Added:
3 years ago
Mitral valve dysfunction is the most common cause of valvular disease in the US.1 Although echocardiography is the primary non-invasive modality for visualizing the mitral valve, advances in technology continue to allow for improved evaluation of mitral disease with magnetic resonance imaging (MRI) and computed tomography (CT).2,3 Currently, the role for MRI and CT assessment of the mitral valve…
View more